Our company: about Singulex
Singulex, Inc. is the developer and leading provider of single molecule counting (SMCTM) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultra-sensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics.
Singulex SMC technology can detect low-abundance biomarkers, such as proteins and nucleic acids, with unparalleled sensitivity and accuracy, capturing concentrations down to the femtogram/mL level. Researchers and physicians now can detect, and monitor changes in, extremely low levels of established disease biomarkers such as cardiac troponin I and cytokines. As a result, scientists and clinicians have gained new molecular insights into, and found new utility for, these biomarkers of disease.
Singulex Clinical Lab Testing Services consists of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing to physicians in the U.S., including proprietary Singulex tests that leverage the company’s SMC technology. Additional Singulex tests in other chronic disease areas are under development.
Singulex Life Sciences Products & Services provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs), and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Erenna system helps power discovery and development of innovative diagnostics and treatments for chronic diseases such as cardiovascular disease, Alzheimer’s disease, oncology, rheumatoid arthritis, and diabetes.
Singulex currently is developing the Singulex Clinical Diagnostic System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. Singulex will seek CE mark and FDA clearance for the new diagnostic system and a series of high-sensitivity tests, currently available only through Singulex’s U.S.-based Clinical Lab Testing Services, enabling patients all over the world to benefit from these advanced diagnostics.
The Singulex Code of Business Conduct and Ethics
The Singulex Code of Business Conduct and Ethics sets forth the general guidelines for conducting the business of Singulex consistent with the highest standards of business ethics. This Code is an important part of the Company’s overall Compliance Program. If you have questions about the Code of Business Conduct and Ethics, please contact the Singulex Compliance Officer at .
Download a copy of Singulex Code of Business Conduct and Ethics here.